

Name: Lorenzo

Surname: Dagna

Mailing address (Work): Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR)
IRCCS San Raffaele Scientific Institute
Vita-Salute San Raffaele University

-
- Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milano
 - Associate Professor of Medicine, Vita-Salute San Raffaele University School of Medicine, Milano
 - Member of the Steering Committee, San Raffaele International MD Program, Vita-Salute San Raffaele University, Milano
 - Coordinator – Teaching activities, Department of Internal Medicine, San Raffaele Scientific Institute, Milano

Education

- Medical Doctor (MD) summa cum laude on July 19, 1999 (Università degli Studi di Milano School of Medicine, Milano)
- Board Certified in Internal Medicine summa cum laude on November 9, 2004 (Università Vita-Salute San Raffaele University, Milano)

Teaching appointments

- Mar 2011 – date : Associate Professor of Medicine, Vita-Salute San Raffaele University School of Medicine, Milan
- Jun 2010 – date: Member of the Steering Committee, San Raffaele International MD Program, Vita-Salute San Raffaele University, Milano
- Oct 2006 – date: Professor, Residency Program in Allergy and Clinical Immunology, Vita-Salute San Raffaele University, Milano
- 2008 – date: Member of Curriculum Committee, Vita-Salute San Raffaele University School of Medicine, Milan
- 2006 – date: Lecturer, European School of Internal Medicine (ESIM), Sintra-Estoril (PT), London (UK), European Federation of Internal Medicine
- Oct 2002 – Feb 2011: Lecturer and clinical Instructor, Vita-Salute San Raffaele University School of Medicine, Milan
- Oct 2006 – Feb 2011: Tutor and Counselor to Medical Students, Vita-Salute San Raffaele University School of Medicine, Milan

Clinical and research activities

- Nov 2016 – date: Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milano
- Mar 2011 – Oct 2016 Coordinator – Clinical Immunology and Rheumatology Unit, Department of Internal Medicine, San Raffaele Scientific Institute, Milano
- Jul 2005 – Feb 2011: Consultant, Unit of Medicine and Clinical Immunology, San Raffaele Scientific Institute, Milano
- Feb 2005 – Jan 2008: Research Fellow in Internal Medicine, Vita-Salute San Raffaele School of Medicine, Milano
- Sep 1999 – Jun 2005: Physician Scientist, Unit of Human Virology, San Raffaele Scientific Institute, Milano
- Oct 1996 – Jun 2005: Intern, Resident and Fellow, Department of Medicine, San Raffaele Scientific Institute, Milano
- Aug 2002, Aug 2003, Jul/Aug 2006, Aug 2007, Aug 2008: Volunteer physician, Sao Marcos Hospital, Paulo de Lima favela, San Salvador, Bahia, Brasil; Barra Hospital, Barra, Bahia, Brasil; St. Raphael of St. Francis Nsambya Hospital, Kampala, Uganda; St. Mary's Lacor Hospital, Gulu, Uganda; ISIC Hospital, New Delhi, India; Orphanages of Brothers and Sisters of Mother Teresa, Gurgaon, India

Research interests

- the pathogenesis and immunotherapy of autoimmune and autoinflammatory diseases;
- the mechanisms of histiocyte recruitment and activation in Erdheim-Chester disease
- the role of infectious agents (and in particular of human herpesviruses) in the pathogenesis of human diseases (and in particular in vasculitides) and the mechanisms such agents exploit to escape immune surveillance
- the role of $\gamma\delta$ T lymphocytes in the immune response against pathogens (and in particular against Mycobacterium tuberculosis) and in the killing of malignant or infected cells;
- the role of the lymphocyte activation-induced cell death in vivo and in vitro, either as a tumor escape mechanism, or as a damaged pathway in the diseases characterized by impaired apoptosis, such as the autoimmune lymphoproliferative syndrome (the Canale-Smith syndrome);

Membership in Professional Societies & Committees

- Fellow of the American College of Physician (ACP)
- Honorary Fellow of the European Federation of Internal Medicine (EFIM)
- Member of the Italian Society for Internal Medicine (SIMI)
- Chair of the Rare Disease Working Group of the European Federation of Internal Medicine (EFIM)
- Member of the Commission Expert Group on Rare Diseases, European Commission (Luxembourg, L)
- Alternate Member of the Healthcare Professionals Working Party of the European Medicine Agency (EMA, London, UK)
- Board Member, Foundation for the Development of Internal Medicine in Europe (FDIME, Geneva)
- Member of the Medical Advisory Board of the Erdheim-Chester Global Alliance (DeRidder, LA)
- Member of the International Foundation of Medicine Oversight Committee of the National Board of Medical Examiners (NBME, Philadelphia, PA)
- Editor for Immunology and Rheumatology for the European Journal of Internal Medicine.

Experience in clinical research

In the past 5 years I served as the Principal Investigator for the following trials:

- *A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)*
- *A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate.*
- *A prospective observational study to assess the real world effectiveness of golimumab (GLM) in patients with active rheumatoid arthritis (RA), psoriatic arthritis (PsA), or axial Spondyloarthritis (axSpA) and failure of an initial tumor necrosis factor alpha inhibitor (TNFai) therapy*
- *A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)- Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/ Azathioprine*
- *Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS) Prospective observational cohort of patients with moderate-to-severe SLE to characterize cross-sectional and longitudinal disease activity, treatment patterns and effectiveness, outcomes and comorbidities, healthcare resource utilization, and the impact of SLE on quality of life by type I interferon gene expression*
- *A Multicentre, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β_2 Agonist in Patients with Uncontrolled Asthma (SIROCCO)*
- *A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)*
- *MAXIMISE (Managing AXIal Manifestations in Psoriatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52-week study to assess the efficacy and safety of secukinumab 150 mg or 300 mg s.c. in patients with active psoriatic arthritis and axial skeleton involvement who have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs)*
- *A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL-301 in giant cell arteritis*
- *A Prospective, Observational Study, in patients with a newly confirmed diagnosis of Spondyloarthritis (SpA) according to ASAS criteria, naïve to conventional (cDMARDs), targeted (tsDMARDs) and biological DMARDs (bDMARDs) – SIRENA Study (Spondyloarthritis Italian Registry: Evidence from a National pathway)*
- *A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, adaptive-design study to evaluate the efficacy, safety and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE) on standard-of-care therapy*
- *A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Atacicept in Reducing Disease Activity in Subjects With Active and Autoantibody-positive Systemic Lupus Erythematosus (SLE) receiving Standard of Care*
- *A randomized, double blind, placebo controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis*
- *A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatica*
- *A Phase 2 dose-ranging study to evaluate the efficacy and safety of AMG 570 in subjects with active systemic lupus erythematosus (SLE) with inadequate response to standard therapy*

- *Phase 4 Placebo Controlled Study to evaluate the efficacy and safety of Apremilast in subjects with early, oligoarticular psoriatic arthritis despite initial stable treatment with either non-steroidal anti-inflammatory drugs (NSAIDs) and/or ≤ 1 conventional synthetic disease-modifying antirheumatic drugs (DMARD)*
- *A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations of patients with Sjögren's Syndrome (TWINSS)"*
- *A multi-center, randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of anifrolumab in adult subjects with active proliferative lupus nephritis in the active phase*
- *Efficacy and safety of sublingual immunotherapy with LAIS Birch Allergoid tablets for patients with allergic rhinoconjunctivitis induced by tree pollen in the presence or absence of controlled mild asthma*
- *A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis*
- *A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis*
- *A randomized, double-blind, double-dummy, active-controlled, multicenter, 2-part Phase II study on replacement of steroids by IFX-1 in active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)*

In the past 5 years, I designed and served as Principal Investigator of the following *investigator initiated studies (IISs)*:

- *A pilot study of tocilizumab in patients with Erdheim-Chester disease*
- *A prospective observational study on the use of biosimilar infliximab in the treatment of Takayasu arteritis resistant to traditional corticosteroid and immunosuppressive therapy*
- *The role of musculoskeletal ultrasound in the therapeutic algorithm of the patient with Psoriatic Arthritis - UPSTREAM*
- *Phenotypic characterization of patients with immune-mediated diseases in current clinical practice (Pan-immuno).*
- *Periostin as a possible biomarker of cutaneous and pulmonary involvement in Systemic Sclerosis (PN-SSc)*
- *Determination of the major allergens responsible for the "Skeeter Syndrome" (the ZANZA protocol)*
- *Characterization of the clinical and biological phenotype of patients with systemic lupus erythematosus in a multicentric cohort: the Milan Lupus Consortium (MLC)*
- *A randomized, double-blind, placebo-controlled, phase IIa monocentric study of subcutaneous anakinra plus standard of care versus standard of care for the treatment of virus-negative myocarditis (MYTH-1)*

With specific regards to the COVID19 epidemic:

- *I serve as the lead for the experimental immunological therapy program for COVID19 epidemic at IRCCS San Raffaele Scientific Institute, Milan, Italy*
- *I serve as a PI for the study: An adaptive phase 2/3, randomized, double-blind, placebo- controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19*
- *I designed and serve as the PI for the IIS: A randomized controlled trial of mavrilimumab to treat acute respiratory failure due to COVID-19 pneumonia: the COMBAT-19 trial*

Publications

For an updated list see:

<https://www.ncbi.nlm.nih.gov/pubmed?term=dagna%20l%5BAuthor%5D>